Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
August 07, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company...
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
August 06, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease - - Three CNS gene therapy programs on...
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment...
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
June 13, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company...
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
June 13, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment...
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
May 16, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first...
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - -...
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
May 08, 2024 06:00 ET
|
Voyager Therapeutics, Inc.
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and...